Non-invasive Detection of IDH-mutant Gliomas using Single and Multi-voxel Point-resolved Spectroscopy

IDH mutation has become one of the most important prognostic biomarkers in glioma management, regardless of histopathological features. The oncometabolite 2HG has been proposed as a biomarker for IDH-specific genetic profiles for gliomas. We report clinical utility of SVS and 1H-MRSI using a long TE (97 ms) in assessing IDH-mutant gliomas by detecting the characteristic resonances of 2HG. Our results from 25 patients showed sensitivity and specificity of 77% and 83%, respectively. In conclusion, 1H-MRS with optimized TE can accurately detect 2HG levels, which has significant clinical implications for determining prognosis and evaluating therapeutic efficacy for targeted and/or alternative therapies.